Scientists test 'Living Drug' from donors to fight tough leukemia
NCT ID NCT05507827
Summary
This early-stage trial is testing the safety of a new, two-part treatment for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or is hard to treat. The treatment involves a strong chemotherapy regimen, a special stem cell transplant (Orca-T), and an infusion of immune cells from a matched donor that are engineered to hunt and kill leukemia cells (CD19/CD22-CAR T cells). The main goal is to see if this combined approach can fight the cancer effectively without causing severe complications from the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford Cancer Center
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.